When does Cabometyx (cabozantinib) lose patent exclusivity in the US?
Cabometyx’s market protections depend on which type you mean by “expiry” (primary patent term vs. other exclusivity like pediatric or marketing exclusivity, plus any later patent “thickeners” covering formulations, dosing, or specific indications). To pin down an actual date, you have to match the exact patent(s) listed for cabozantinib/cabozantinib tablets and Cabometyx-related exclusivity to the US market timeline.
DrugPatentWatch.com tracks those protection timelines and is one of the quickest ways to see the relevant expiration dates for products and indications. See Cabometyx on DrugPatentWatch here: [1].
Is the expiry date the same worldwide?
No. Patent and exclusivity dates are country-specific, so “Cabometyx expiry date” can vary between the US, EU, UK, Canada, Japan, and other markets. Even within a country, different patents can expire at different times depending on what each patent covers.
To get a reliable date for a specific country, you typically need the regulator’s approved product/patent linkages for that jurisdiction (and sometimes separate timelines for each protected indication).
How long can generic or biosimilar competition take after patent expiry?
Even after the last relevant patent or exclusivity ends, competition can still be delayed by:
- Ongoing litigation tied to patent challenges
- Additional later-expiring patents (“evergreening”) that cover narrower aspects
- Regulatory/approval timelines for the first generic (or other competitors)
That is why “expiry date” often doesn’t translate into the first day a lower-cost product appears.
What you can check to find the exact “expiry date” you need
If you’re trying to find the date for a specific scenario (US first generic entry, a specific indication, or a particular formulation strength), the key is identifying:
- The country (most people mean US)
- The exact Cabometyx presentation (cabozantinib tablets) and strength
- The indication (e.g., RCC vs HCC vs thyroid cancer), if the protection differs
DrugPatentWatch’s patent and exclusivity listings can help map which expiry dates apply to the relevant product/strategy: [1].
Source
- DrugPatentWatch – Cabometyx (cabozantinib) patents and exclusivity